CHEK1 and triple-negative breast carcinoma: Lim et al. [77] reported that recovery of hsa-miR-320c expression could increase the responsiveness to oxaliplatin in triple-negative breast cancer (TNBC) through targeting checkpoint kinase 1 (Chk1), which regulated DNA damage responses.